Further studies are needed to elucidate the contribution of specific ILC populations in cancer and to better understand whether the immunosuppressive activity of TGF-β may depend on its capability to modify phenotypic and functional properties of these effector lymphocytes. The gene discussed is TGFB1; the disease is cancer.